- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04151498
HIV Reengagement and Assessment Mobile Program (Project RAMP)
Project RAMP (Reengagement and Assessment Mobile Program): A Field Visit Model for HIV Clinic Reengagement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall purpose of the Project RAMP intervention is to find out what challenges make it hard for people living with HIV to keep their in-person clinic appointments. The investigators also hope to learn how much a mobile HIV treatment van may help patients who have been out of care for a minimum of 6 months, to re-start keeping regular clinic visits. The investigators also hope this information will help be useful in learning best practices for providing health care to people living with HIV.
This study will recruit a total of 30 participants, 20 for the intervention and 10 for the usual care group. Participants will be recruited through bridge counselors at the partnering clinic, whose roles and responsibilities consist of finding and reaching out to patients who have been out of HIV care in an attempt to get them reengaged.
Participants will have up to 5 study visits that are between 1- 4 weeks apart. Each visit will last about 1 to 1.5 hours. Participants will also be asked to participate in two in depth interview: a baseline interview at the start of the study that will ask questions about each participant's experience with their past clinic visits and an exit interview at the end of the study regarding their experience participating in the HIV mobile treatment program (Project RAMP). The pre-intervention visit (Visit 0) includes the first interview, providing some brief information about you, a urine pregnancy test for participants who are female, and a brief meeting with a financial technician who will help participants complete their insurance information. Intervention Visit 1 will include a nurse from the partnering clinic administering the video educational intervention, HIV medication adherence counseling, a health history form, blood draws for standard reengagement labs (CD4 count, HIV viral load, comprehensive metabolic panel, complete blood count with differential, rapid plasma reagin and HIV genotype). Specimens from these visits will be delivered to partnering clinic for analysis. Notes from the mobile visit will be shared with the study PI, who will in term communicate these notes with the assigned clinic provider of each participant. Visits 2-4 will include a study nurse conducting additional blood draws if recommended by their assigned provider, and a review of adherence counseling and health history forms.
At the end of each intervention visit, participants will be if they would like to make an in person clinic appointment. Those who decline at the end of intervention Visits 1-3 will be offered an additional field visit appointment. Those who decline an in person clinic appointment at the end of Visit 4 will move on to completing the exit interview in person at this time and will complete the study following the exit interview. Participants who schedule a clinic appointment will have their exit interview in person or via phone within 3 months of their clinic visit. All participants will be follow up to 6 months after their last study visit to to access their viral load, if this information is available.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina at Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18 years
- HIV positive
- Referred to the bridge counselors by the partnering clinic as out of care for >=6 months and not successfully re-engaged in care by a bridge counselor
- Willing and able to give informed consent and adhere to study visits
Exclusion Criteria:
- Unwilling or physically unable to participate in study visits on the mobile van
- Lack of English language fluency
- Planning or preferring to transfer HIV care to an HIV clinic other than the partnering HIV clinic
- Pregnant women will be expedited into clinical care and will not be eligible for the study
- Presence of mobility or balance issues that prevent patient from safely stepping up onto the mobile unit without assistance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group
This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
|
Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement.
The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
Other Names:
Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
|
|
Other: Usual Care Reengagement Group
This group will complete a qualitative interview about barriers and facilitators to HIV care.
|
Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
|
|
No Intervention: Non-enrolling Group
This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of eligible persons screened that enroll.
Time Frame: Screening call through Visit 0 when consent occurs, approximately 2 - 3 weeks
|
Percentage of all eligible persons that are screened by the study team that enroll in Project RAMP during the intervention period.
|
Screening call through Visit 0 when consent occurs, approximately 2 - 3 weeks
|
|
Qualitative Summary of Participants' Experiences from In-depth Baseline Interview
Time Frame: Up to approximately 1 hour at Baseline
|
Data will be obtained from in-depth qualitative interviews.
Summary will include reasons why patients who have been out of care for more than 6 months have been lost to care.
|
Up to approximately 1 hour at Baseline
|
|
Qualitative Summary of Participants' Experiences from In-depth Exit Interview
Time Frame: Up to approximately 1 hour at Exit Interview
|
Data will be obtained from in-depth qualitative interviews.
Summary will include information evaluating participants' experiences in Project RAMP.
|
Up to approximately 1 hour at Exit Interview
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who are successfully reengaged following the intervention.
Time Frame: 6 months following the participants' last intervention visit
|
Reengagement is defined as 1 kept visit following the intervention.
The investigators will collect this data from the participants' medical record.
|
6 months following the participants' last intervention visit
|
|
Number of participants who are successfully retained following the intervention.
Time Frame: 6 months following the participants' last intervention visit
|
Retention is defined as 2 kept visits following the intervention.
The investigators will collect this data from the participant's medical record.
|
6 months following the participants' last intervention visit
|
|
Number of participants who have viral suppression following the intervention.
Time Frame: 6 months following participants' last intervention visit
|
Viral suppression is defined as <200 copies/mL.
The investigators will collect data on viral suppression from participant's medical record.
|
6 months following participants' last intervention visit
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christopher Sellers, MD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 19-0664
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Reengagement and Assessment Mobile Program
-
Griffith UniversityNot yet recruitingChronic Kidney DiseaseVietnam
-
Marta MarciniakRecruiting
-
Saglik Bilimleri UniversitesiNot yet recruiting
-
Ad scientiamCompleted
-
PepsiCo Global R&DRecruiting
-
Allina Health SystemCompletedChemotherapy-induced Peripheral NeuropathyUnited States
-
Rafael StelmachFederal University of AmazonasCompleted
-
Universidad Autonoma de MadridUniversidad Rey Juan CarlosNot yet recruitingFibromyalgia (FM)
-
Chang Gung Memorial HospitalUnknown
-
Fidan BalkayaInonu UniversityActive, not recruitingMOBILE WEB-BASED INTERVENTION PROGRAM | NURSING EDUCATION STRESS | SLEEP QUALITYTurkey (Türkiye)